Cercano Management LLC Grows Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Cercano Management LLC boosted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 4.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 213,068 shares of the medical device company’s stock after purchasing an additional 9,108 shares during the quarter. Cercano Management LLC owned about 0.06% of DexCom worth $26,440,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Citizens Financial Group Inc. RI purchased a new stake in shares of DexCom in the fourth quarter valued at $222,000. Motley Fool Asset Management LLC raised its stake in shares of DexCom by 6.9% in the fourth quarter. Motley Fool Asset Management LLC now owns 10,647 shares of the medical device company’s stock valued at $1,321,000 after acquiring an additional 684 shares during the period. Syon Capital LLC raised its stake in shares of DexCom by 9.7% in the fourth quarter. Syon Capital LLC now owns 4,549 shares of the medical device company’s stock valued at $564,000 after acquiring an additional 401 shares during the period. Pittenger & Anderson Inc. purchased a new stake in shares of DexCom in the fourth quarter valued at $349,000. Finally, Tokio Marine Asset Management Co. Ltd. raised its stake in shares of DexCom by 3.3% in the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 9,703 shares of the medical device company’s stock valued at $1,204,000 after acquiring an additional 307 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on DXCM shares. Canaccord Genuity Group raised their price target on shares of DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a research note on Friday. Royal Bank of Canada started coverage on shares of DexCom in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price target on the stock. StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research note on Tuesday, April 23rd. Citigroup raised their price target on shares of DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Finally, UBS Group raised their price target on shares of DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and a consensus price target of $141.67.

DexCom Stock Down 9.9 %

Shares of NASDAQ:DXCM traded down $13.67 during trading on Friday, reaching $124.34. The stock had a trading volume of 8,578,184 shares, compared to its average volume of 2,409,208. DexCom, Inc. has a one year low of $74.75 and a one year high of $142.00. The company has a market capitalization of $49.24 billion, a P/E ratio of 80.22, a PEG ratio of 2.14 and a beta of 1.20. The company has a current ratio of 2.84, a quick ratio of 2.48 and a debt-to-equity ratio of 1.18. The firm’s 50-day simple moving average is $131.13 and its 200 day simple moving average is $118.53.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. DexCom had a net margin of 16.82% and a return on equity of 31.38%. The business had revenue of $921.00 million for the quarter, compared to analysts’ expectations of $911.20 million. As a group, research analysts expect that DexCom, Inc. will post 1.78 EPS for the current fiscal year.

Insider Activity

In other news, EVP Sadie Stern sold 20,321 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $133.61, for a total value of $2,715,088.81. Following the sale, the executive vice president now directly owns 80,441 shares in the company, valued at approximately $10,747,722.01. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Kevin R. Sayer sold 81,007 shares of the stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $133.36, for a total value of $10,803,093.52. Following the completion of the transaction, the chief executive officer now directly owns 333,526 shares of the company’s stock, valued at approximately $44,479,027.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Sadie Stern sold 20,321 shares of the stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $133.61, for a total transaction of $2,715,088.81. Following the completion of the transaction, the executive vice president now directly owns 80,441 shares of the company’s stock, valued at $10,747,722.01. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 189,375 shares of company stock worth $25,530,859. Corporate insiders own 0.41% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.